Vanda Pharmaceuticals shares jump 30% after FDA approval of Fanapt for bipolar I disorder

The biopharmaceutical company said Tuesday the latest marketing approval increases the commercial opportunity of the treatment.

Previous post Intel foundry losses expected to peak this year after hitting $7 billion in 2023
Next post Auto sales dip in March due to high prices and high borrowing rates